Search
Agios Pharmaceuticals Inc
AGIOAdd to Watchlist
34.190USD
-0.780-2.23%
Close 09-23 16:00（ET）
2.03BMarket Cap
LossP/E TTM
Agios Pharmaceuticals Inc (AGIO) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Agios Pharmaceuticals Inc in the past month.
Buy
3 Strong Buy
4 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
48.000USD+37.26%
AGIO Analyst Recommendation Trends
In the current month, AGIO has received 4 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. AGIO average Analyst price target in the last month is 48.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
10
10
10
10
10
AGIO Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, AGIO EPS is projected to reach -1.214 in FY2026Q3, following reported EPS of -1.693 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.95
-1.80
-1.67
-1.21
-1.08
Actual
-1.85
-1.69
-1.69
--
--
Surprise
+4.87%
+6.37%
-1.49%
--
--
FAQs
What is Agios Pharmaceuticals Inc's expected revenue for the next quarter?
Agios Pharmaceuticals Inc's expected revenue is 53.76M.
What is Agios Pharmaceuticals Inc's price target?
Analysts forecast that Agios Pharmaceuticals Inc's price target is USD 48.00, with the highest forecast at USD 73.00 and the lowest forecast at USD 32.00.
How have Agios Pharmaceuticals IncAGIO's recent earnings per share performed?
The market expectation was USD -1.69, while Agios Pharmaceuticals IncAGIO's earnings per share (EPS) for the previous quarter was USD -1.69. EPS for the next quarter is expected at USD -1.21.
What is the analyst rating for Agios Pharmaceuticals Inc?
Based on the ratings of Agios Pharmaceuticals Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.